IDRA 21

Synonyms: IDRA 21, 7,8-dihydro-8-oxo-7-(2-hydroxyethyl)-9H-purine-6-carboxaldehyde, 7,8-dihydro-8-oxo-7-(2-hydroxyethyl)guanine, 8-oxo-7-(2-hydroxyethyl)guanine, 22503-72-6

IDRA 21 is a synthetic purine derivative that has garnered attention in neuropharmacology as a positive allosteric modulator of the AMPA receptor. Its chemical structure, featuring a 7,8-dihydro-8-oxo-purine core with a 2-hydroxyethyl side chain, distinguishes it from other AMPA receptor modulators and contributes to its unique pharmacological profile. While not a natural product, IDRA 21 is often studied alongside endogenous purines due to its structural similarity to guanine derivatives.

Initially identified through screening efforts aimed at finding cognitive enhancers, IDRA 21 has become a valuable tool compound for investigating glutamatergic signaling. Unlike direct AMPA receptor agonists, it modulates receptor activity by slowing desensitization, thereby enhancing synaptic responses without inducing excitotoxicity. This mechanism has positioned it as a candidate for addressing cognitive deficits in neurological disorders.

In research settings, IDRA 21 is primarily used to probe the role of AMPA receptors in learning and memory processes. Its ability to cross the blood-brain barrier and its favorable pharmacokinetic profile in animal models make it a subject of interest for preclinical studies. While not yet approved for clinical use, IDRA 21 continues to be a reference compound in the development of next-generation cognitive enhancers.

Function

• AMPA receptor potentiation: Enhances glutamate-induced currents by reducing receptor desensitization.
• Cognitive enhancement: Improves performance in various animal models of learning and memory.
• Neuroprotection: May protect against excitotoxic damage under certain conditions.
• Synaptic plasticity modulation: Influences long-term potentiation (LTP) and long-term depression (LTD).
• Research tool: Widely used to study glutamatergic transmission in vitro and in vivo.

Source & Standardization

• Source: Synthetic chemical synthesis
• Extraction: Not applicable (synthetic)
• Standardization: ≥98% purity by HPLC
• Forms: Crystalline powder
• Applications: Neuropharmacology research, cognitive enhancement studies, AMPA receptor research

Specifications

Documentation & Supply

• Monthly capacity: 10 kg
• Lead time: 3-5 business days (stock items)
• Documentation: COA, MSDS, TDS available upon request
• Packaging: Amber glass vials or aluminum foil bags

Request For Quote

• LyvBio Co., Ltd. — Email: info@lyvbio.com